A possible mechanism of response differentiation between BM and EM sites. Compared to EM sites (for example, skin), BM might have a higher concentration of blinatumomab, more cytotoxic T cell (CTLs), and less inhibitory signals (PD-L1/PD-1), as well as a higher level of CD19 in leukemic cells.